Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Deferred Revenue: 2024-2025

Historic Current Deferred Revenue for Kura Oncology (KURA) over the last 1 years, with Sep 2025 value amounting to $48.8 million.

  • Kura Oncology's Current Deferred Revenue was N/A to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year change of. This contributed to the annual value of $24.3 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Kura Oncology reported Current Deferred Revenue of $48.8 million as of Q3 2025, which was down 1.39% from $49.4 million recorded in Q2 2025.
  • Kura Oncology's 5-year Current Deferred Revenue high stood at $49.4 million for Q2 2025, and its period low was $24.3 million during Q4 2024.
  • Its 2-year average for Current Deferred Revenue is $40.8 million, with a median of $44.8 million in 2025.